IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 19, 2016, Pages E2705-E2713

  Fu, Amy K Y ^a   Hung, Kwok Wang ^a   Yuen, Michael Y F ^a   Zhou, Xiaopu ^a   Mak, Deejay S Y ^a   Chan, Ivy C W ^a   Cheung, Tom H ^a   Zhang, Baorong ^b   Fu, Wing Yu ^a   Liew, Foo Y ^c,d   Ip, Nancy Y ^a  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d SOOCHOW UNIVERSITY   (China)

Author keywords

Innate immunity; Microglia neuroninflammation; Synaptic plasticity; amyloid

Indexed keywords

CD68 ANTIGEN; CRYOPYRIN; INTERLEUKIN 1BETA; INTERLEUKIN 33; INTERLEUKIN 6; PROTEIN; PROTEIN ST2; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; CYTOKINE; IL33 PROTEIN, MOUSE; NEUROPROTECTIVE AGENT;

ADULT; ALZHEIMER DISEASE; AMNESIA; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; CELL LOSS; CONTROLLED STUDY; GENE EXPRESSION; MACROPHAGE; MICROGLIA; MILD COGNITIVE IMPAIRMENT; MOUSE; NERVE CELL; NERVE CELL PLASTICITY; NONHUMAN; PATHOGENESIS; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; ANIMAL; BRAIN; COGNITION DISORDERS; DRUG EFFECTS; FEMALE; MALE; METABOLISM; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ALZHEIMER DISEASE; ANIMALS; BRAIN; COGNITION DISORDERS; CYTOKINES; FEMALE; INTERLEUKIN-33; MALE; MICE; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; TREATMENT OUTCOME;

EID: 84966429058     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1604032113     Document Type: Article

References (57)

1. Alzheimer's Association (2015) 2015 Alzheimer's disease facts and figures. Alzheimers Dement 11(3):332-384.
2. McKhann G, et al. (1984) Clinical diagnosis of Alzheimer's disease:Reportofthe NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34(7): 939-944.
3. Carrillo MC, et al. (2013) Revisiting the framework of the National Institute on Aging-Alzheimer's Association diagnostic criteria. Alzheimers Dement 9(5):594-601.
4. Tanzi RE (2012) The genetics of Alzheimer disease. Cold Spring Harb Perspect Med 2(10):a006296.
5. Heppner FL, Ransohoff RM, Becher B (2015) Immune attack: The role of inflammation in Alzheimer disease. Nat Rev Neurosci 16(6):358-372.
6. Vom Berg J, et al. (2012) Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat Med 18(12):1812-1819.
7. Heneka MT, et al. (2013) NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 493(7434):674-678.
8. Guillot-Sestier M-V, et al. (2015) Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. Neuron 85(3):534-548.
9. Chakrabarty P, et al. (2015) IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron 85(3):519-533.
10. Liew FY, Pitman NI, McInnes IB (2010) Disease-associated functions of IL-33: The new kid in the IL-1 family. Nat Rev Immunol 10(2):103-110.
11. Han P, Mi WL, Wang YQ (2011) Research progress on interleukin-33 and its roles in the central nervous system. Neurosci Bull 27(5):351-357.
12. Gadani SP, Walsh JT, Smirnov I, Zheng J, Kipnis J (2015) The glia-derived alarmin IL-33 orchestrates the immune response and promotes recovery following CNS injury. Neuron 85(4):703-709.
13. Yasuoka S, et al. (2011) Production and functions of IL-33 in the central nervous system. Brain Res 1385:8-17.
14. Molofsky AB, Savage AK, Locksley RM (2015) Interleukin-33 in tissue homeostasis, injury, and inflammation. Immunity 42(6):1005-1019.
15. Chapuis J, et al. (2009) Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease. Mol Psychiatry 14(11):1004-1016.
16. Jankowsky JL, et al. (2004) Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: Evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13(2):159-170.
17. Jacobsen JS, et al. (2006) Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 103(13):5161-5166.
18. Fu AK, et al. (2014) Blockade of EphA4 signaling ameliorates hippocampal synaptic dysfunctions in mouse models of Alzheimer's disease. Proc Natl Acad Sci USA 111(27): 9959-9964.
19. Minogue AM, et al. (2014) Age-associated dysregulation of microglial activation is coupled with enhanced blood-brain barrier permeability and pathology in APP/PS1 mice. Neurobiol Aging 35(6):1442-1452.
20. Montagne A, et al. (2015) Blood-brain barrier breakdown in the aging human hippocampus. Neuron 85(2):296-302.
21. Mucke L, Selkoe DJ (2012) Neurotoxicity of amyloid β-protein: Synaptic and network dysfunction. Cold Spring Harb Perspect Med 2(7):a006338.
22. Malm TM, Jay TR, Landreth GE (2015) The evolving biology of microglia in Alzheimer's disease. Neurotherapeutics 12(1):81-93.
23. Gomez-Nicola D, Perry VH (2015) Microglial dynamics and role in the healthy and diseased brain: A paradigm of functional plasticity. Neuroscientist 21(2):169-184.
24. Wang Y, et al. (2015) TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 160(6):1061-1071.
25. Yamada Y, Doi T, Hamakubo T, Kodama T (1998) Scavenger receptor family proteins: Roles for atherosclerosis, host defence and disorders of the central nervous system. Cell Mol Life Sci 54(7):628-640.
26. de Villiers WJ, Smart EJ (1999) Macrophage scavenger receptors and foam cell formation. J Leukoc Biol 66(5):740-746.
27. Derecki NC, Katzmarski N, Kipnis J, Meyer-Luehmann M (2014) Microglia as a critical player in both developmental and late-life CNS pathologies. Acta Neuropathol 128(3): 333-345.
28. Zhou X, He X, Ren Y (2014) Function of microglia and macrophages in secondary damage after spinal cord injury. Neural Regen Res 9(20):1787-1795.
29. Zhang GX, Li J, Ventura E, Rostami A (2002) Parenchymal microglia of naïve adult C57BL/6J mice express high levels of B7.1, B7.2, and MHC class II. Exp Mol Pathol 73(1): 35-45.
30. Malito E, Hulse RE, Tang WJ (2008) Amyloid beta-degrading cryptidases: Insulindegrading enzyme, presequence peptidase, and neprilysin. Cell Mol Life Sci 65(16): 2574-2585.
31. Heneka MT, et al. (2015) Neuroinflammation in Alzheimer's disease. Lancet Neurol 14(4):388-405.
32. Ousman SS, Kubes P (2012) Immune surveillance in the central nervous system. Nat Neurosci 15(8):1096-1101.
33. McLaren JE, et al. (2010) IL-33 reduces macrophage foam cell formation. J Immunol 185(2):1222-1229.
34. Miller AM, et al. (2008) IL-33 reduces the development of atherosclerosis. J Exp Med 205(2):339-346.
35. Stewart CR, et al. (2010) CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 11(2):155-161.
36. Mawuenyega KG, et al. (2010) Decreased clearance of CNS beta-amyloid in Alzheimer's disease.Science 330(6012):1774.
37. Hickman SE, Allison EK, El Khoury J (2008) Microglial dysfunction and defective betaamyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci 28(33): 8354-8360.
38. Bennett ML, et al. (2016) New tools for studying microglia in the mouse and human CNS. Proc Natl Acad Sci USA 113(12):E1738-E1746.
39. Miners JS, Barua N, Kehoe PG, Gill S, Love S (2011) Aβ-degrading enzymes: Potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol 70(11):944-959.
40. Iwata N, et al. (2013) Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice. Sci Rep 3:1472.
41. Huang SM, et al. (2006) Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. J Biol Chem 281(26): 17941-17951.
42. Gadani SP, Walsh JT, Lukens JR, Kipnis J (2015) Dealing with danger in the CNS: The response of the immune system to injury. Neuron 87(1):47-62.
43. Wada J, Makino H (2016) Innate immunity in diabetes and diabetic nephropathy. Nat Rev Nephrol 12(1):13-26.
44. O'Neill LA, Golenbock D, Bowie AG (2013) The history of Toll-like receptors: Redefining innate immunity. Nat Rev Immunol 13(6):453-460.
45. Neher JJ, et al. (2011) Inhibition of microglial phagocytosis is sufficient to prevent inflammatory neuronal death. J Immunol 186(8):4973-4983.
46. Jana M, Palencia CA, Pahan K (2008) Fibrillar amyloid-beta peptides activate microglia via TLR2: Implications for Alzheimer's disease. J Immunol 181(10):7254-7262.
47. Costello DA, Carney DG, Lynch MA (2015) α-TLR2 antibody attenuates the Aβ-mediated inflammatory response in microglia through enhanced expression of SIGIRR. Brain Behav Immun 46:70-79.
48. Liu J, Buckley JM, Redmond HP, Wang JH (2010) ST2 negatively regulates TLR2 signaling, but is not required for bacterial lipoprotein-induced tolerance. J Immunol 184(10):5802-5808.
49. Brint EK, et al. (2004) ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol 5(4):373-379.
50. Schmitz J, et al. (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23(5):479-490.
51. Yu JT, et al. (2012) Implication of IL-33 gene polymorphism in Chinese patients with Alzheimer's disease. Neurobiol Aging 33(5):1014.e11-1014.e14.
52. Spencer B, Masliah E (2014) Immunotherapy for Alzheimer's disease: Past, present and future. Front Aging Neurosci 6:114.
53. Oakley H, et al. (2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: Potential factors in amyloid plaque formation. J Neurosci 26(40):10129-10140.
54. Xu D, et al. (2008) IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci USA 105(31):10913-10918.
55. Sananbenesi F, et al. (2007) A hippocampal Cdk5 pathway regulates extinction of contextual fear. Nat Neurosci 10(8):1012-1019.
56. Ip FC, et al. (2015) Anemoside A3 enhances cognition through the regulation of synaptic function and neuroprotection. Neuropsychopharmacology 40(8):1877-1887.
57. Nikodemova M, Watters JJ (2012) Efficient isolation of live microglia with preserved phenotypes from adult mouse brain. J Neuroinflammation 9:147.